Abstract: Materials and methods for preparing reactive lignin and for preparing a bio-based adhesive are described herein.

Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

Abstract: The invention provides lipid A mimics in which one or both of the sugar residues of a natural lipid A disaccharide backbone has been replaced with an aromatic group. These lipid A mimics may further differ from a natural lipid A molecule with respect to other structural characteristics, such as, a different number of phosphate groups present, changes in the number, structure and location of lipid chains and/or changes in the spacing and linkage of the sugar residues (or their aromatic replacements). The lipid A mimics may be lipid A agonists and as such may be useful as immunostimulatory agents in inducing or patenting an antibody and/or cell-mediated immune response, or may be lipid A antagonists and as such may be useful in treating or preventing a lipopolysaccharide (LPS)/lipid A-mediated disease or disorder. Also provided are methods for preparing the lipid A mimics.

Abstract: Glycosphingolipids (GSLs) compositions and methods for iNKT-independent induction of chemokines are disclosed.

Abstract: The invention relates to C-3 novel triterpenone with C-17 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

Abstract: It is described a Clostridium difficile (C-difficile) toxins A and/or B as a target for therapy, including passive immunotherapy, and particularly prevention of C-difficile intoxication in human or other animals. It is also described a polypeptide comprising a portion of C-difficile toxins A and/or B sequence being an epitope for anti-toxins A and/or B antibody. It is also disclosed a method for generating a neutralizing antibody directed against C-difficile toxins A and/or B. It is also provided a novel formulation that combines key toxins A and/or B epitope antibodies, located in three key domains of toxins A and/or B, for neutralizing toxins A and/or B, at any stage of toxins A and/or B intoxication related to C-difficile infection. The novel formulation of toxins A and/or B epitope antibodies are useful in immunotherapy, for therapeutic and/or prophylactic mediation of C-difficile intoxication.

Abstract: The invention discloses a freeze-dried powder of high molecular weight silk fibroin, preparation process and use thereof. The freeze-dried powder is obtained from silk by degumming, dissolution, dialysis, centrifugation, high temperature and high pressure treatment and freeze-drying. A method of preparing silk fibroin microspheres with polyethylene glycol comprises mixing a silk fibroin solution of 1-30 wt % with a PEG solution of 10-60 w % and incubating the resulting solution. A controlled-release or sustained-release silk fibroin gel formulation includes a gel-state carrier and a drug dispersed/adsorbed therein, the carrier is a silk fibroin gel formed by blending with LMW-PEG.

Abstract: Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.

Abstract: The present invention provides peptides comprising a sequence of X?6X?5X?4X?3X?2X?1X1PX3X4PX6X7PGX10X11AX13X14X15X16LX18X19X20X21X22X23LX25X26 YLX29X30X31X32 (SEQ ID NO: 13) wherein the amino acids X?6, X?5, X?4, X?3, X?2, X?1, X1, X3, X4, X6, X7, X10, X11, X13, X14, X15, X16, X18, X19, X20, X21, X22, X25, X26, X29, X30, X31, and X32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.

Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

Abstract: Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Abstract: Provided herein are integrin antagonists and methods of using the same. For example, one or more of the compounds or polypeptides provided herein can be used in the treatment of disorders such as heart attacks, stroke, and cancer metastasis. Also provided herein is a crystal comprising ?v?3 ectodomain complexed with inhibitor knottin 2.5 F. Further provided herein is a crystal comprising ?V?3 ectodomain complexed with inhibitor hFN10. In another aspect, the invention features a method that includes using a three-dimensional model of a complex that includes an integrin ectodomain.

Abstract: Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as Pichia pastoris, and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant.

Abstract: The present disclosure relates to a human CK8 antigen peptide, an antibody, or antibody fragment thereof, or a humanized antibody, specifically binding the peptide having the amino acid sequence of SEQ ID No. 29, a fragment of CK-8. Said molecules can be used use in the detection and/or treatment of tumors whose cells express CK8 protein, in particular the peptide of sequence according to SEQ ID No.29, on their surface.

Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

Abstract: The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.

Abstract: The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore.

Abstract: Provided are novel seizure related 6 (SEZ6) modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders.

Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: Provided is a fusion protein comprising an agonist for CD40 and an agonist for OX40. Compositions comprising the fusion protein and methods of use are also provided.

Abstract: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.

Abstract: In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and/or therapeutic targeting of CD46-overexpressing tumors.

Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.

Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.

Abstract: The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.

Abstract: The present invention provides a dispersion liquid of anion-modified cellulose nanofibers and a composition of anion-modified cellulose nanofibers that are not colored when heated. Specifically, the dispersion liquid contains anion-modified cellulose nanofibers; an anti-coloring agent selected from the group consisting of borate salts and sulfite salts, or combinations thereof in an amount of 1 to 30 mass % based on an absolute dry mass of the anion-modified cellulose nanofibers; and a solvent.

Abstract: A hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent. A process of preparing a hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules.

Abstract: The present invention provides a modified conjugated diene-based polymer which includes a functional group derived from a substituted styrene-based compound and a functional group derived from an aminosilane-based compound, a method for preparing the same, and a rubber composition including the same. The modified conjugated diene-based polymer includes the functional group derived from an aminosilane-based compound of Formula 1 and a functional group derived from a substituted styrene-based compound of Formula 2 at both terminals of a main chain, and thus, shows a high modification ratio. When applying the polymer in a rubber composition, excellent affinity with a filler may be shown, and as a result, agglomeration of a filler in the rubber composition may be prevented, and the dispersibility of the filler may be increased, thereby improving the processability of the rubber composition.

Abstract: This invention relates to a supported catalyst system and process for use thereof. In particular, the catalyst system includes a pyridyldiamido transition metal complex, a metallocene compound, a support material and, optionally, an activator. The catalyst system may be used for preparing multi-modal polyolefins.

Abstract: The invention pertains to peroxide-curable fluoroelastomers for the oil and gas industry, including explosive decompression, and which can be easily processed to yield cured parts in standard machineries at reasonable throughput rates, said fluoroelastomers comprising: recurring units derived from vinylidene fluoride (VDF); recurring units derived from hexafluoropropylene (HFP); recurring units derived from at least one bis-olefin [bis-olefin (OF)] having general formula: wherein R1, R2, R3, R4, R5 and R6, equal or different from each other, are H, a halogen, or a C1-C5 optionally halogenated group, possibly comprising one or more oxygen group; Z is a linear or branched C1-C18 optionally halogenated alkylene or cycloalkylene radical, optionally containing oxygen atoms, or a (per)fluoropolyoxyalkylene radical; and iodine or bromine cure-sites; said fluoroelastomers further possessing a Mooney viscosity (ML) of at least 85 MU (1+10@121° C.), when measured according to ASTM D1646.

Abstract: A photocurable composition contains a polymerizable compound; and a photopolymerization initiator, in which the photocurable composition contains a compound represented by General Formula (1) shown below as the polymerizable compound, and in which, in General Formula (1), Ar represents a monovalent aromatic group which may have a substituent, R1 represents an alkyl group which may have a substituent or a hydrogen atom, R2 represents an alkyl group having (m+n) valences which may have a substituent, m is an integer of 2 or more, and n is an integer of 1 or more.

Abstract: Disclosed is a block copolymer including: at least one block A not including any phosphonate group, and including at least one poly(alkylene oxide) group and at least one block B obtained by polymerization of a monomer B1 or of a mixture of monomers with ethylenic unsaturation including at least one monomer B1, wherein a monomer B1 is a monomer with ethylenic unsaturation including at least one phosphonate function, to its preparation method by RAFT controlled radical polymerization and to its uses.

Abstract: Disclosed are compositions that comprise water and a polyether polyol derived from sucrose and an alkylene oxide, as well as polyurethane foam systems comprising such compositions, methods for their production, and the resulting polyurethane foams.

Abstract: The present invention provides polyurethanes including a reaction product of components including: (a) an isocyanate functional urethane prepolymer comprising a reaction product of components including: (i) about 1 equivalent of at least one polyisocyanate; and (ii) about 0.1 to about 0.5 equivalents of at least one diol having 2 to 18 carbon atoms; and (b) about 0.05 to about 0.9 equivalents of at least one branched polyol having 4 to 18 carbon atoms and at least 3 hydroxyl groups; and (c) up to about 0.9 equivalents of at least one polyol different from branched polyol (b) and having 2 to 18 carbon atoms, wherein the reaction product components are essentially free of polyester polyol and polyether polyol; compositions, coatings and articles made therefrom and methods of making the same.

Abstract: The present disclosure relates to a cyclic polysulfane-based polymer, a cyclic polysulfane-polynorbornene block copolymer, a method of preparing the cyclic polysulfane-based polymer, a method of preparing the cyclic polysulfane-polynorbornene block copolymer, and a film including the cyclic polysulfane-polynorbornene block copolymer.

Abstract: Provided is a fluorine atom-containing polymer which is a condensation polymer of a fluorene derivative that provides a repeating unit represented by formula (1), a fluorene derivative that provides a repeating unit represented by formula (2) and a fluorene derivative that provides a repeating unit represented by formula (3).

Abstract: Disclosed are mixtures containing: mono- and bi-functional polymers [polymers (P-A) and (P—B)] comprising a plurality of (per)fluoropolyether segments [segments (SRF)] joined together by hydrogenated (poly)ether segments [segments (SH)], said polymers having two ends, wherein one or both ends comprises a hydroxy or a leaving group; a non-functional polymer comprising a plurality of (per)fluoropolyether segments (SRF) joined together by hydrogenated (poly)ether segments (SH), with the proviso that the hydrogenated (poly)ether segments (SH) are not segments of formula —CH2OCH2OCH2—. Disclosed are also monofunctional polymers (P-A) that can be isolated from such mixtures. Methods for the obtainment of the mixtures and for separating the polymers therein contained are also provided, as well as methods of using the mixtures or each polymer therein contained as intermediates or building blocks for the synthesis of other polymers or as ingredients of compositions.

Abstract: The production method of the present invention includes: a supplying step of supplying reaction raw materials to at least one of a plurality of reaction vessels that mutually communicate through a gas phase; a polymerizing step of carrying out a polymerization reaction; and a step of removing at least some of the water present in the reaction vessels. Each of the steps is carried out in parallel, and a reaction mixture is transferred sequentially between the reaction vessels. The amount of water contained in the reaction mixture in at least one of the reaction vessels is from 0.1 moles to less than 3 moles per mole of a sulfur source, and the total amount of water contained in the reaction raw materials that are supplied is 3 moles or more per mole of the sulfur source.

Abstract: A 2-cyanoethyl-containing organoxysilane compound having the formula: NC—CH2—CH2—X—Si(OR1)3 is heat resistant and compatible with organic solvents. R1 is a C1-C20 monovalent hydrocarbon group, and X is a C2-C20 divalent hydrocarbon group which contains a methylene and/or methine moiety, at least one of the methylene and methine moieties being substituted with a divalent heteroatom linking moiety NR (wherein R is hydrogen, C1-C20 monovalent hydrocarbon group or 2-cyanoethyl), a trivalent heteroatom linking moiety N, or a combination thereof.

Abstract: Provided are rapidly cross-linkable silicone compositions, systems, kits, and methods for filling implanted medical devices in situ, the implanted medical devices, including for example, body implants and tissue expanders, the compositions including a platinum divinyl disiloxane complex; a low viscosity vinyl terminated polydimethylsiloxane; a low viscosity hydride terminated polydimethylsiloxane; and a silicone cross-linker, where the rapidly cross-linkable silicone composition has a viscosity of ?150 cPs for ?1 min. post-preparation and ?300 cPs?5 min. post-preparation, at ambient temperature.

Abstract: The present invention relates to a process for the preparation of a block copolymer comprising a first type of polyolefin block and at least one type of second polymer block, the process comprising the steps of: A) polymerizing at least one type of olefin monomer using a catalyst system to obtain a first polyolefin block containing a main group metal on at least one chain end; the catalyst system comprising: i) a metal catalyst or metal catalyst precursor comprising a metal from Group 3-10 of the IUPAC Periodic Table of elements; and ii) at least one type of chain transfer agent; and iii) optionally a co-catalyst; B) reacting the first polyolefin block containing a main group metal on at least one chain end obtained in step A) with at least one type of oxidizing agent and subsequently at least one type of metal substituting agent to obtain a first polyolefin block containing at least one functionalized chain end; C) forming at least one second polymer block on the first polyolefin block, wherein as an initiat

Abstract: The purpose of the present invention is to provide: a resin composition which enables the achievement of a pearly molded body having good pearly texture; and a pearly molded body. A resin composition for pearly molded bodies, which is to be melt-kneaded and molded together with an aromatic polyester, and which contains a polyolefin (excluding a low-density polyethylene having a density of 0.92 g/cm3 or less) and an acid-modified polyolefin. It is preferable that the acid-modified polypropylene has an acid value of 1-60 mg KOH/g. It is also preferable that the acid-modified polypropylene is contained in an amount of 1-1,900 parts by mass relative to 100 parts by mass of the polyolefin.

Abstract: The invention relates to a method and a device for bonding two substrates, wherein an adhesive is applied to a first substrate and a second film-type substrate consisting of a thermoplastic material is converted into a plasticized state by heating before being bonded to the first substrate.

Abstract: The present invention relates to a polymer film comprising a base film comprising polyamide-based resin; and two or more kinds of copolymers comprising polyamide-based segments and polyether-based segments, and a method for preparing the polymer film.

Abstract: Copolymers having thiophene based and vinylene based moieties. Methods of producing the copolymers, and methods of utilizing the copolymers as chromogenic sensors for selective detection of iodide anion are also provided.

Abstract: A method of transfer printing comprises globally heating an array of stamps, where each stamp comprises a shape memory polymer with a light absorbing agent dispersed therein, and pressing the array of stamps to a donor substrate comprising a plurality of inks. Each stamp is thereby compressed from an undeformed adhesion-off configuration to a deformed adhesion-on configuration. The array of stamps is then cooled to rigidize the shape memory polymer and bind the plurality of inks to the stamps in the deformed adhesion-on configuration. The plurality of inks remain bound to the stamps while the array of stamps is positioned in proximity with a receiving substrate. A selected stamp in the array is then locally heated using a concentrated light source. The selected stamp returns to the undeformed adhesion-off configuration, and the ink bound to the selected stamp is released and transfer printed onto the receiving substrate.